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INTRODUCTION
Glucagon-like peptide 1 (GLP-1) is the best studied gut-derived incretin hormone. The incretin effect describes the phenomenon that glucose triggers a stronger increase in insulin secretion when given orally as compared with an intravenous infusion; the higher insulin secretion is observed when oral or intravenous glucose are compared for their insulin releasing effects under conditions when they lead to the same changes in blood glucose levels [1] [2] [3] .
Because of their capacity to increase insulin secretion and to inhibit pancreatic glucagon secretion, GLP-1 receptor (GLP-1R) agonists and inhibitors of dipeptidyl peptidase-IV (DPP-IV), which reduce the breakdown of endogenous GLP-1, are cornerstones of today's antidiabetic therapy. A second boost to the study of GLP-1mediated effects followed the observation that some effects of bariatric surgery, in particular of the Roux-en-Y gastric bypass (RYGB) and the vertical sleeve gastrectomy (VSG) may depend on the exaggerated secretion of gut hormones, including GLP-1, after surgery. The contribution of GLP-1 to bariatric surgery benefits is still a matter of debate, but it is clear that GLP-1 produces a large number of effects (e.g. reduction in eating; increase in insulin secretion) that are also induced by RYGB and VSG [4] [5] [6] . The potent reduction in eating by GLP-1 led to the recent approval of the GLP-1R agonist liraglutide for the treatment of obesity in the USA. a Institute of Veterinary Physiology, Vetsuisse Faculty University of Zurich, (http://www.fda.gov/NewsEvents/Newsroom/Press Announcements/ucm427913.htm).
The first randomized trial indicated that liraglutide treatment over 1 year as an adjunct to diet and exercise was associated with reduced body weight and improved metabolic control in a population of nondiabetic patients with dyslipidaemia or hypertension [7 && ]. In particular, the fasting lipid profile was markedly improved in the liraglutide-treated patients, including significant decreases in total cholesterol and plasma triglycerides (TAG), and increases in HDL cholesterol (HDL-C).
Hence, beyond the well studied incretin effects, this class of hormones exerts a number of pleiotropic actions that may be beneficial in cardiometabolic disease. The main topic of this brief review is to summarize effects of incretins, in particular GLP-1, but also of GLP-2, on lipid metabolism. We will concentrate on the recently published literature on extrapancreatic effects of GLP-1 and GLP-2. Glucose-dependent insulinotropic polypeptide (GIP; also called gastric inhibitory polypeptide) is another hormone with well known incretin action but GIP's role in the control of lipid metabolism is less clear than for GLP-1. GIP is known to improve LDL clearance, but at the same time to favour an unhealthy type of fat distribution with a decrease in subcutaneous and an increase in intra-abdominal fat [8 & ]. Hence, more research needs to be done to better understand the role of GIP in lipid metabolism.
Dyslipidaemia, which frequently accompanies diseases like the metabolic syndrome and type 2 diabetes mellitus contributes to the elevated risk of cardiovascular disease under these conditions. The proatherosclerotic lipid abnormalities include elevated levels of plasma TAG and TAG-rich VLDL and chylomicrons. Further, dyslipidaemia includes high levels of LDL cholesterol (LDL-C) together with low levels of HDL-C. Quantitative but also qualitative changes in lipoprotein structure and function, for example, altered glycation and oxidation of lipoprotein particles and altered function of HDL-C, are present [9 & ,10,11 && ].
The alterations in lipoprotein metabolism mutually influence each other; elevated TAG-rich lipoproteins contribute to lower HDL levels and to elevated levels of LDL. Further, insulin resistance and type 2 diabetes mellitus are associated with an increased production of TAG-rich lipoproteins in the intestine [characterized by their apolipoprotein (Apo)B-48 content] and in the liver (characterized by ApoB-100) (for review: [12, 13] ). In particular, the intestinal production of lipoproteins is modulated by GLP-1 but also GLP-2. Although it is derived from the same preproglucagon gene [14] and is released from the same intestinal L cells in the same molar ratio as GLP-1, GLP-2 does not exert incretin actions.
Production site of glucagon-like peptide-1 and glucagon-like peptide-2
GLP-1 and GLP-2 are secreted from enteroendocrine L cells [1, 15] . Two important issues are unclear. First, it is unknown which part of the gastrointestinal tract contributes most to circulating GLP-1 because the density of the GLP-1 and GLP-2 producing L cells is higher in distal parts of the small intestine and in the colon, but the highest total number of L cells at least in rats is in the jejunum [16] . Second, L cells express various receptors and transporters that trigger L-cell secretion in response to a large variety of stimuli, such as glucose, long or short-chain fatty acids but also bile acids [17] . However, it is a matter of debate which of these stimuli contributes most to the postprandial release of GLP-1 and GLP-2; there are even more uncertainties about their contribution to the elevated basal and postprandial GLP-1 and GLP-2 levels after RYGB or VSG because of the altered transit of the food and anatomical rearrangement of the gut after these procedures [16, [18] [19] [20] [21] [22] 23 && ]. GLP-1 is also produced in a subset of neurons in the nucleus of the solitary tract (NTS). GLP-1 analogues have recently been shown to control intestinal lipoprotein secretion when administered directly into the central nervous system [24 && ], whether this effect mimics the action of GLP-1 released from NTS neurons and whether this has a specific role in the control of lipid metabolism needs further clarification.
Sites of glucagon-like peptide-1 action to increase insulin secretion and to reduce eating [25] , but part of the effect may also depend on activation of vagal afferent neurons [26] . GLP-1's eating inhibitory effect also depends on a paracrine action via intestinal vagal afferents, which transmit the signal to the NTS [27] . Whether a direct action of endogenous GLP-1 on the brain also plays a role for the eating inhibitory effect under physiological conditions is a matter of debate; this may be different from exogenously applied GLP-1 agonists like liraglutide because their direct access to the brain is facilitated by the compound's chemical structure [28] . Details for the site of GLP-1's effects on lipid metabolism will be discussed in the subsequent sections; depending on the target organ, part of the effects seems to be direct (e.g. on intestinal epithelial cells), and part seems indirect (e.g. central nervous system-mediated effects on the liver). . Improved lipaemia typically includes reduced levels of LDL-C, total cholesterol, and TAG. A network meta-analysis has recently reviewed the most important clinical studies, which prove the beneficial effects of such treatment on dyslipidaemia [29 & ]. GLP-1 agonists and DPP-IV inhibitors do not consistently increase HDL-C levels [29 & ] which at first sight may seem counterintuitive. It is important to highlight that the vascular-protective properties of HDL may be more relevant than the HDL-C concentration alone to inhibit atherosclerosis [31 && ]. Along this line, in a recent study early after RYGB, elevated plasmatic GLP-1 levels were associated with an improved capacity of HDL to stimulate excessive cholesterol efflux from macrophages; further, at the endothelial level, HDL stimulation induced nitric oxide production, and exerted anti-inflammatory and antiapoptotic actions not only in a rat RYGB model but also in patients. Interestingly, liraglutide treatment in diet-induced obese rats rapidly improved the functions of HDL and mimicked the beneficial effect of RYGB surgery. This functional improvement occurred despite unchanged HDL-C concentration [23 && ]. Liraglutide also seems to affect the distribution of cholesterol within specific lipoprotein subclasses. In patients, liraglutide caused a shift away from small, dense LDL particles, and it decreased the apolipoprotein B concentration [30] . In our own study, we showed that the HDL-C particle size was shifted toward smaller size HDL particles by RYGB surgery in diet-induced obese rats, and this effect was mimicked by liraglutide [23 && ]. Recent evidence suggests that small dense HDL particles may be of clinical relevance as a major mediator of the cardiovascular protective properties of HDL [32,33 & ]. Finally, indirect evidence also supports a role of GLP-1 in improved lipaemia after RYGB, because the most pertinent changes like decreased postprandial LDL-C and TAG, and increased HDL-C after RYGB were best predicted by the associated GLP-1 peak [34] .
Glucagon-like peptide-1 and lipid metabolism
Regarding atherosclerosis, which is the vascular consequence of chronic pathologic alterations in lipid levels, DPP-IV inhibition has been shown to reduce plaque inflammation and increase plaque collagen content in respective mouse models [35, 36] . GLP-1 and its split products were reported to reduce plaque vulnerability in a mouse model of vascular disease without affecting atherosclerotic lesion size [37] . Further, liraglutide treatment seemed to prevent and stabilize early onset atherosclerotic vascular disease partially through GLP-1Rdependent mechanisms but had no significant effect on the progression of late onset, high-burden atherosclerotic disease [38] . Recently, treatment with engineered fusion proteins constituted by GLP-1 fused to the globular domain of adiponectin has been reported to reduce atherosclerosis and glucose intolerance in ApoEÀ/À mice fed a highfat diet [39] . To the best of our knowledge, there are no published studies assessing specifically the role of GLP-2 on atherosclerosis processes or plaque vulnerability.
Role of the intestine in glucagon-like peptide-1's effects on blood lipids
Intestinal and hepatic metabolism of lipids and lipoproteins are the two major players affecting lipaemia. A number of studies suggest that GLP-1 may influence both organs in a different way: with a direct local action at the intestinal level and with an indirect modulation on the liver. GLP-1 agonism has been shown to reduce the activity of jejunal microsomal triglyceride transfer protein and of jejunal TAG availability in hamsters. Further, the reduction in the concentration of chylomicrons was due to reduced production rather than increased clearance of these compounds. Hence, GLP-1 agonists (e.g. exendin-4) and reduced GLP-1 breakdown (e.g. by sitagliptin) in experimental animals or in humans lead to a direct reduction in intestinal lipoprotein synthesis so that less TAG and less ApoB-48 reached the circulation after oral lipid administration [40,41 && ,42]; to our knowledge, it is unclear how the TAG that are not packaged into chylomicrons will eventually be metabolized. Exendin-4 or sitagliptin also reduced postprandial free fatty acid levels in patients [41 && ,43] .
Direct action in the intestine
It is generally believed that the above-mentioned effects are direct effects at the intestinal level, for example on intestinal ApoB-48 production. A direct mode of action is also supported by in-vitro studies with isolated hamster enterocytes because exendin-4 inhibited ApoB-48 secretion also under these conditions [11 && ,42] . The molecular mechanisms of GLP-1's influence on chylomicron synthesis, assembly, and secretion in enterocytes are still unknown.
Indirect action via the brain Indirect actions may to some extent contribute to GLP-1's effects on intestinal lipid and lipoprotein handling. These may, for example include a reduction in the rate of gastric emptying and gastric lipase activity, which lead to a lower availability and lower rate of processing of dietary fat. Indirect effects mediated by GLP-1 action in the central nervous system may also play some role, but more detailed studies will be necessary in the future [11 && ,24 && ] (see also below).
Role of the liver and brown adipose tissue in glucagon-like peptide-1's effects on blood lipids
Dyslipidaemia in obesity and diabetes are associated with alterations in hepatic lipid metabolism. At least some of these alterations can be corrected by GLP-1. GLP-1 agonists, for example reduce hepatic VLDL overproduction and de novo lipogenesis in hamsters. These effects were associated with decreased hepatic lipid accumulation, and a decrease in circulating VLDL-bound TAG and plasmatic ApoB-100 [44 & ].
Indirect action via insulin release and the brain
In contrast to GLP-1's effect in the intestine, most of GLP-1's hepatic effects seem to be mediated indirectly. The antilipolytic effect and the effect to lower free fatty acids, TAG-rich VLDL, and chylomicrons seem to be driven by insulin; hence, they depend on GLP-1's incretin effect [11 && ,40] . Part of these effects may also be mediated by the central nervous system because centrally administered exendin-4 increases peripheral energy utilization and decreases hepatic lipid synthesis. Because the effect was blocked by vagotomy, modulation of parasympathetic nerve activity may mediate part of the indirect effects of GLP-1 on the liver [44 & ].
Indirect action via the sympathetic nervous system and brown fat Finally, increased peripheral energy utilization may result from an enhanced burning of fat and an activation of brown adipose tissue function [44 & ,45 & ]. The latter effect may also be mediated by the central nervous system because GLP-1 increases thermogenesis via the brain and because central exendin-4 has been shown to increase brown adipose tissue function and subsequently to lower TAG levels [45 & ]. The effects of central exendin-4 to reduce the TAG content in lipoproteins and to reduce ApoB-48 seem to be mediated via sympathetic nervous system activation [24 && ] and may therefore also be linked to an enhanced burning of fat. The reduction of ApoB-48 observed after central administration of exendin-4 indicates that the reduced chylomicron formation by enterocytes depends on direct activation of intestinal GLP-1 receptors (as discussed above) and GLP-1-mediated central nervous system effects via sympathetic activation [24 && ]. The effects of central exendin-4 on peripheral lipid metabolism seem to be independent of exendin-4's effects on food intake or body weight [46] .
Effect of glucagon-like peptide-1 to improve hepatic steatosis
Exendin-4 or liraglutide has been shown to reduce the occurrence and degree of hepatic steatosis independent of their action on body weight [47] . These effects were observed in experimental animals but also in the clinical setting. Liraglutide, for example improves metabolic dysfunction and insulin resistance, reduces lipotoxicity in the liver, and counteracts the pathogenesis of nonalcoholic hepatic steatosis [48,49 & ].
Indirect action via enhanced insulin release and sensitivity
Similar to GLP-1's hepatic action on circulating lipids, this effect seems to be indirect and related to increased insulin release and sensitivity [48] . The beneficial effects on hepatic lipid accumulation and on metabolic parameters in fatty liver disease seem to be because of reduced inflammation and endoplasmic reticulum stress [50] . The antioxidative and anti-inflammatory effects were also associated with an inactivation of the proinflammatory c-Jun N-terminal kinase pathway [49 & ]. Further, the antioxidative, cell-protective levels of glutathione were increased by exendin-4, which suggests that GLP-1 receptor agonists play a beneficial role against increased oxidative stress [51] .
Glucagon-like peptide-1 mediated but glucagon-like peptide-1R-independent processes
In some, but not all previously discussed studies, the effects of GLP-1 agonists or inhibitors of GLP-1 breakdown were suggested to be mediated by the GLP-1R because of their reversal after administration of the receptor blocker exendin-9. We and others, however, reported actions of GLP-1 or of its split products, which appear to be mediated by an additional not yet identified GLP-1 receptor system [37] . In our recent experiments, we compared effects of RYGB surgery and of direct GLP-1 receptor activation on the cardiovascular system and parameters of lipoprotein metabolism in rats. The beneficial effects of RYGB on the vascular endothelium were mimicked by liraglutide and blocked by exendin-9, which suggests an involvement of the known GLP-1R [23 && ]. In the same study, however, we also observed that GLP-1 favoured lipid metabolism by a mechanism that presumably was independent of the known GLP-1R [23 && ]. In other words, GLP-1 mimicked RYGB effects on the circulating lipoprotein concentration and function, but these effects were not blocked by exendin-9, that is, HDL properties were not impaired in RYGB rats receiving exendin-9 chronically [23 && ]. It remains to be clarified which type of receptor may be responsible for the latter liraglutide-induced effects.
Glucagon-like peptide-1 versus glucagonlike peptide-2
In contrast to the effects of GLP-1, GLP-2 has recently been demonstrated to enhance intestinal lipoprotein release. In hamsters, GLP-2 stimulated enterocyte fat absorption and intestinal chylomicron output [42,52,53 && ]. The mechanism of action is not clear because the GLP-2 receptor is not expressed in enterocytes; whether this indicates that the relevant receptor still needs to be identified, or that the effect is indirect, needs to be investigated. Blockade of nitric oxide synthesis reduced the GLP-2-stimulated secretion of ApoB-48, and nitric oxide donors increased the release of TAG-rich lipoproteins in vivo and in vitro; hence, nitric oxide seems to be required for the mobilization and secretion of stored TAG after GLP-2 stimulation. Similarly, GLP-2 stimulation also led to a rapid increase in ApoB-48 and enhanced the secretion of intestinal apolipoprotein in humans [54] .
Interestingly, GLP-1 reduces and GLP-2 increases intestinal chylomicron release. This supports the idea that the two hormones are part of the fine regulation of intestinal chylomicron metabolism with opposite counterregulatory effects. A recent study in hamsters showed that an acute coinfusion of GLP-1 and GLP-2 resulted in a net increase in lipid absorption, associated with increased TAG and ApoB-48. In contrast, an extended 2-h coinfusion or a blockade of GLP-1
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Eating SNS activation FIGURE 1. Summary of glucagon-like peptide-1 (GLP-1)-mediated effects on lipid metabolism. GLP-1, which is released from intestinal L cells acts directly on the intestine, the brown adipose tissue, the brain, and the pancreas. The latter effects contribute to GLP-1's effects on hepatic lipid metabolism and eventually on blood lipid levels. For details, please see text. Red: inhibitory effect; green: stimulatory effect. breakdown by DPP-IV inhibition decreased postprandial lipaemia. It, therefore, seems that acutely, the effect of GLP-2 may dominate, but sustained GLP-1 activity will eventually result in lower lipoprotein levels [52] .
CONCLUSION
The review briefly summarizes some recent findings on the effects of GLP-1 and GLP-2 on lipoprotein metabolism (Fig. 1) . Pharmacological activation of the GLP-1 system has clear beneficial effects on lipoprotein metabolism. Effects can be observed with direct GLP-1R agonists like liraglutide or exendin-4, but also with DPP-IV inhibitors, which reduce the breakdown of endogenous GLP-1. It needs to be shown that the effects of GLP-1 activation will eventually translate into a lower cardiovascular risk. Understanding the control of lipoprotein metabolism by GLP-1 may offer new insights into the development of new strategies to treat dyslipidaemia. Overall, the described effects may be an important basis for the further development of drugs to treat dyslipidaemia in obesity, diabetes, and other cardiometabolic diseases.
